Research
Hormonal
GLP-1 receptor agonists (RAs) have revolutionized treatment for type 2 diabetes mellitus and its comorbidities, including obesity and cardiovascular disease.
GLP-1 RAs should be considered as a treatment option for managing type 2 diabetes and associated conditions.
StrongSupportsmedium confidence
In the last decade, the glucagon-like peptide-1 (GLP-1) receptor agonist (RA) drug class has revolutionized treatment for type 2 diabetes mellitus and some of its comorbidities, including obesity and cardiovascular disease.
Why this rating
The claim is based on a comprehensive overview of the GLP-1 RA class.
Source
GLP-1 RAs
Evan S. Drake et al. · The Nurse Practitioner · 2024
DOI 10.1097/01.npr.0000000000000216
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →